<DOC>
	<DOCNO>NCT02053935</DOCNO>
	<brief_summary>This clinical study drug name dopamine affect body ability make secrete insulin . Insulin hormone make pancreas help body regulate sugar level . We think drug decrease amount insulin body make cause sugar level high . When critically ill many adverse effect sugar level high .</brief_summary>
	<brief_title>Impact Dopamine Infusion Insulin Secretion Healthy Subjects</brief_title>
	<detailed_description>Rationale Role dopamine infusion pancreatic beta cell function health disease remain undetermined human . Increasingly , hyperglycemia critical care arena bode poorly health outcome . This study first time investigate role dopamine infusion health potential guide large study impact dopamine use critical illness . Study Design This project prospective , single-center trial determine effect dopamine healthy subject use hyperglycemic clamp . Study Procedures : After sign informed consent subject undergo screen clinical research center overnight fast . At visit , complete history physical exam include vital sign , height , weight , BMI , waist circumference obtain . Cardiac condition screen use EKG . Baseline labs drawn visit , include CBC , chemistry , liver function test , hemoglobin AIC , thyroid function test , lipid cortisol . Females urine beta HCG . Subjects meet study criterion return within 30 day screen clinical research overnight fast . One large bore ( 20 gauge ) venous cannula insert antecubital fossa infusion dopamine dextrose 20 % intravenous solution . Another cannula insert contralateral arm frequent blood sampling . Insulin sensitivity determine use gold standard hyperglycemic clamp previously describe ( DeFronzo , 1979 ) .13 Each subject act control receive placebo infusion follow dopamine infusion . Subjects blood pressure , heart rate , glucose monitor every 10 minute . Each subject receive priming dose dextrose 20 % increase glucose concentration 125 mg/dl first 15 minute . Then receive variable rate dextrose 20 % infusion maintain glucose level 180-220 mg/dl . C-peptide , insulin , glucagon catecholamine level draw 30 min 60 min determine baseline level prior dopamine infusion . Then , dopamine ( 200mg/250ml ) titrate 5 mcg/kg/min care increase blood pressure great 160 systolic . C-peptide , insulin level , glucagon , plasma catecholamine measure 90 min 120 min , 150min , 180min , 210min , 240min . At 120min , 180 min 240 min glucagon cortisol level also measure . The total amount blood withdrawn entire study le 100 ml . After blood sample draw , dextrose dopamine infusion down-titrated stopped . The subject give lunch glucose level check . Venous cannula remove subject send home .</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Dopamine Agents</mesh_term>
	<criteria>1 . Healthy subject 2 . Age 1835 year 3 . Hemoglobin &gt; 12 g/dl 4 . Euthyroid stable dose synthroid 5 . Normal EKG , hemoglobin AIC , kidney liver function 1 . Prior history dopamine infusion 2 . Past medical history diabetes , hypertension , myocardial infarction , vasoocclusive disease arrhythmias 3 . Chronic steroid therapy , oral contraceptive pill , monoamine oxidase inhibitor ( MAOI ) , anticonvulsant ( phenytoin ) 4 . Pregnant woman dopamine pregnancy category C 5 . Clinical sign polycystic ovarian syndrome 6 . Past medical history Cushing 's disease pheochromocytoma 7 . Sulfa drug allergy 8 . Use medication illness determine investigator may affect insulin secretion insulin sensitivity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Dopamine</keyword>
	<keyword>hyperglycemic clamp</keyword>
	<keyword>sepsis</keyword>
	<keyword>hyperglycemia</keyword>
	<keyword>insulin secretion</keyword>
</DOC>